- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
UTHR Market Currents
more »
-
April 26 United Therapeutics (UTHR): Q1 EPS of $1.32 beats by $0.32. Revenue of $204M (+25.7% Y/Y) in-line. (PR)
Comment![Earnings, Healthcare]
UTHR Related Articles
more »
UTHR News
more »
-
at CNBC.com (Feb 29, 2012)
-
at CNBC.com (Feb 14, 2012)
-
at MarketWatch.com (Jan 5, 2012)
-
at MarketWatch.com (Aug 24, 2011)
-
at MarketWatch.com (Jun 20, 2011)
UTHR Press Releases and Filings
more »
-
PR Newswire (Apr 26, 2012)
-
PR Newswire (Apr 19, 2012)
-
PR Newswire (Mar 15, 2012)
-
PR Newswire (Dec 27, 2011)
UTHR Latest Transcript
more »
-
Thu, Apr 26
UTHR Cramer
more »
-
Thu, Mar 1
-
Mon, Nov 5, 2007
-
Fri, Aug 4, 2006
UTHR Instablog posts
more »
UTHR vs. ETF Alternatives
Company Description
We are a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Our key therapeutic platforms are:
Prostacyclin Analogues, which are stable synthetic... More
